Erratum: COVID-19 Lombardy ICU Network. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy (JAMA Intern Med. (2020) 180:10 (1345-1355) DOI: 10.1001/jamainternmed.2020.3539);Risk Factors Associated with Mortality among Patients with COVID-19 in Intensive Care Units in Lombardy, Italy

JAMA Internal Medicine

Volumn 180, Issue 10, 2020, Pages 1345-1355

  Grasselli, Giacomo ^a,b   Greco, Massimiliano ^c,d   Zanella, Alberto ^a,b   Albano, Giovanni ^e   Antonelli, Massimo ^f,g   Bellani, Giacomo ^h,i   Bonanomi, Ezio ^j   Cabrini, Luca ^k   Carlesso, Eleonora ^b   Castelli, Gianpaolo ^l   Cattaneo, Sergio ^m   Cereda, Danilo ⁿ   Colombo, Sergio ^o   Coluccello, Antonio ^p   Crescini, Giuseppe ^p   Forastieri Molinari, Andrea ^q   Foti, Giuseppe ^h,i   Fumagalli, Roberto ^h,r   Iotti, Giorgio Antonio ^s,t   Langer, Thomas ^h,r   Latronico, Nicola ^m,u   Lorini, Ferdinando Luca ^j   Mojoli, Francesco ^s,t   Natalini, Giuseppe ^v   Pessina, Carla Maria ^w   Ranieri, Vito Marco ^x   Rech, Roberto ^y   Scudeller, Luigia ^a   Rosano, Antonio ^v   Storti, Enrico ^z   Thompson, B Taylor ^aa   Tirani, Marcello ^n,ab   Villani, Pier Giorgio ^z   Pesenti, Antonio ^a,b   Cecconi, Maurizio ^c,d   more..

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d HUMANITAS UNIVERSITY   (Italy)

^e Humanitas Gavazzeni Hospital   (Italy)

^f FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^g CATHOLIC UNIVERSITY   (Italy)

^h UNIVERSITY OF MILANO BICOCCA   (Italy)

ⁱ SAN GERARDO HOSPITAL   (Italy)

^j PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^k UNIVERSITY OF INSUBRIA   (Italy)

^l CARLO POMA HOSPITAL   (Italy)

^m SPEDALI CIVILI   (Italy)

ⁿ Division Life Style for Prevention Health Promotion Screening   (Italy)

^o SAN RAFFAELE HOSPITAL   (Italy)

^p CREMONA HOSPITAL   (Italy)

^q A MANZONI HOSPITAL   (Italy)

^r OSPEDALE NIGUARDA CA GRANDA   (Italy)

^s FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^t UNIVERSITY OF PAVIA   (Italy)

^u UNIVERSITY OF BRESCIA   (Italy)

^v Fondazione Poliambulanza   (Italy)

^w ASST Rhodense   (Italy)

^x UNIVERSITY OF BOLOGNA   (Italy)

^y UNIVERSITY OF MILAN   (Italy)

^z Dept of Obstetrics and Gynecology   (Italy)

^aa MASSACHUSETTS GENERAL HOSPITAL   (United States)

^ab Health Protection Agency   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ASSISTED VENTILATION; BLOOD OXYGEN TENSION; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CORONAVIRUS DISEASE 2019; CRITICALLY ILL PATIENT; EXTRACORPOREAL OXYGENATION; FEMALE; FOLLOW UP; FRACTION OF INSPIRED OXYGEN; GROUPS BY AGE; HEART DISEASE; HOSPITAL DISCHARGE; HOSPITAL MORTALITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INTENSIVE CARE UNIT; INTERMITTENT MANDATORY VENTILATION; INVASIVE VENTILATION; ITALY; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MORTALITY RATE; NASOPHARYNGEAL SWAB; NON INSULIN DEPENDENT DIABETES MELLITUS; NONINVASIVE VENTILATION; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POSITIVE END EXPIRATORY PRESSURE VENTILATION; PRIORITY JOURNAL; PRONE POSITION; REAL TIME REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; ARTIFICIAL VENTILATION; BETACORONAVIRUS; CORONAVIRUS INFECTION; CRITICAL ILLNESS; EPIDEMIOLOGY; HOSPITALIZATION; ISOLATION AND PURIFICATION; LABORATORY TECHNIQUE; MIDDLE AGED; MORTALITY; PANDEMIC; PROCEDURES; VIRUS PNEUMONIA;

BETACORONAVIRUS; CLINICAL LABORATORY TECHNIQUES; CORONAVIRUS INFECTIONS; CRITICAL ILLNESS; FEMALE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; INTENSIVE CARE UNITS; ITALY; MALE; MIDDLE AGED; MORTALITY; PANDEMICS; PNEUMONIA, VIRAL; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 85088825454     PISSN: 21686106     EISSN: 21686114     Source Type: Journal    
DOI: 10.1001/jamainternmed.2021.1229     Document Type: Erratum

References (33)

1. Covid-19 coronavirus pandemic. Updated July 3, 2020. Accessed April 12, 2020. https://www.worldometers.info/coronavirus
2. Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. JAMA. Published online March 13, 2020. doi: 10.1001/jama.2020.4031 32167538
3. Lombardia Notizie Online. Posted November 7, 2019. Accessed April 12, 2020. https://www.regione.lombardia.it/wps/portal/istituzionale/HP/lombardia-notizie
4. Du RH, Liu LM, Yin W, Hospitalization and critical care of 109 decedents with COVID-19 pneumonia in Wuhan, China. Ann Am Thorac Soc. 2020. doi: 10.1513/AnnalsATS.202003-225OC 32255382
5. Grasselli G, Zangrillo A, Zanella A,; COVID-19 Lombardy ICU Network. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574-1581. doi: 10.1001/jama.2020.5394 32250385
6. Guan WJ, Ni ZY, Hu Y,; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382 (18): 1708-1720. doi: 10.1056/NEJMoa2002032 32109013
7. Huang C, Wang Y, Li X, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395 (10223): 497-506. doi: 10.1016/S0140-6736(20)30183-5 31986264
8. Wang D, Hu B, Hu C, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020. doi: 10.1001/jama.2020.1585 32031570
9. Wang Y, Lu X, Li Y, Clinical course and outcomes of 344 intensive care patients with COVID-19. Am J Respir Crit Care Med. 2020; 201 (11): 1430-1434. doi: 10.1164/rccm.202003-0736LE 32267160
10. Richardson S, Hirsch JS, Narasimhan M,; and the Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052-2059. doi: 10.1001/jama.2020.6775 32320003
11. Myers LC, Parodi SM, Escobar GJ, Liu VX. Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California. JAMA. 2020;323(21):2195-2198. doi: 10.1001/jama.2020.7202 32329797
12. Bhatraju PK, Ghassemieh BJ, Nichols M, COVID-19 in critically ill patients in the Seattle region-case series. N Engl J Med. 2020; 382 (21): 2012-2022. doi: 10.1056/NEJMoa2004500 32227758
13. Anguiano L, Riera M, Pascual J, Soler MJ. Circulating ACE2 in cardiovascular and kidney diseases. Curr Med Chem. 2017; 24 (30): 3231-3241. doi: 10.2174/0929867324666170414162841 28413960
14. Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med. 2020; 27 (3): taaa041. doi: 10.1093/jtm/taaa041 32186711
15. Ortiz-Pérez JT, Riera M, Bosch X, Role of circulating angiotensin converting enzyme 2 in left ventricular remodeling following myocardial infarction: a prospective controlled study. PLoS One. 2013; 8 (4): e61695. doi: 10.1371/journal.pone.0061695 23630610
16. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020; 17 (5): 259-260. doi: 10.1038/s41569-020-0360-5 32139904
17. Hoffmann M, Kleine-Weber H, Schroeder S, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 181 (2): 271-280.e8. doi: 10.1016/j.cell.2020.02.052 32142651
18. Arentz M, Yim E, Klaff L, Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020;323(16):1612-1614. doi: 10.1001/jama.2020.4326 32191259
19. Yang X, Yu Y, Xu J, Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8 (5): 475-481. doi: 10.1016/S2213-2600(20)30079-5 32105632
20. Zhou F, Yu T, Du R, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395 (10229): 1054-1062. doi: 10.1016/S0140-6736(20)30566-3 32171076
21. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. 2nd ed. Wiley; 2002. doi: 10.1002/9781118032985
22. Carenzo L, Costantini E, Greco M, Hospital surge capacity in a tertiary emergency referral centre during the COVID-19 outbreak in Italy. Anaesthesia. 2020; 75 (7): 928-934. doi: 10.1111/anae.15072 32246838
23. Azoulay E, Pochard F, Chevret S,; PROTOCETIC Group. Compliance with triage to intensive care recommendations. Crit Care Med. 2001; 29 (11): 2132-2136. doi: 10.1097/00003246-200111000-00014 11700409
24. Robert R, Reignier J, Tournoux-Facon C,; Association des Réanimateurs du Centre Ouest Group. Refusal of intensive care unit admission due to a full unit: impact on mortality. Am J Respir Crit Care Med. 2012; 185 (10): 1081-1087. doi: 10.1164/rccm.201104-0729OC 22345582
25. Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. JAMA. Published online April 24, 2020. doi: 10.1001/jama.2020.6825 32329799
26. Bellani G, Laffey JG, Pham T,; LUNG SAFE Investigators; ESICM Trials Group. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016; 315 (8): 788-800. doi: 10.1001/jama.2016.0291 26903337
27. Ferrario CM, Jessup J, Chappell MC, Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005; 111 (20): 2605-2610. doi: 10.1161/CIRCULATIONAHA.104.510461 15897343
28. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004; 43 (5): 970-976. doi: 10.1161/01.HYP.0000124667.34652.1a 15007027
29. Jiang F, Yang J, Zhang Y, Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets. Nat Rev Cardiol. 2014; 11 (7): 413-426. doi: 10.1038/nrcardio.2014.59 24776703
30. Karram T, Abbasi A, Keidar S, Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure. Am J Physiol Heart Circ Physiol. 2005; 289 (4): H1351-H1358. doi: 10.1152/ajpheart.01186.2004 15894569
31. Sánchez-Aguilar M, Ibarra-Lara L, Del Valle-Mondragón L, Rosiglitazone, a ligand to PPAR γ, improves blood pressure and vascular function through renin-angiotensin system regulation. PPAR Res. 2019; 2019: 1371758. doi: 10.1155/2019/1371758 30863432
32. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020. doi: 10.1001/jama.2020.6019 32282022
33. Alhazzani W, Møller MH, Arabi YM, Surviving Sepsis Campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med. 2020; 46 (5): 854-887. doi: 10.1007/s00134-020-06022-5 32222812